Circular RNA circ-FOXP1 induced by SOX9 promotes hepatocellular carcinoma progression via sponging miR-875-3p and miR-421

Wang, Wei; Li, Yuan; Li, Xiuling; Liu, Bowei; Han, Sun‐Young; Li, Xiaofang; Zhang, Bingyong; Li, Jian; Sun, Suofeng

doi:10.1016/j.biopha.2019.109517

Cited by 65 publications

(37 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the aforementioned 16 miRNAs, the overexpression of hsa-miR-939 was correlated with poor prognosis in lung cancer (38), as well as promoting epithelial to mesenchymal transition in epithelial ovarian cancer (39). It has been reported that hsa-miR421 promotes tumor progression in hepatocellular carcinoma (40) and osteosarcoma (41), and hsa-miR-335 participates in the progression of gallbladder carcinoma (42). On the other hand, hsa-miR-582 functions as a tumor suppressor in colorectal cancer (43) and hsa-miR-1254 inhibits cell migration and invasion in gastric cancer (44).…”

Section: Discussionmentioning

confidence: 99%

A novel microRNA signature for pathological grading in�lung adenocarcinoma based on TCGA and GEO data

Yang

Yin²,

Shi

et al. 2020

Int J Mol Med

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAd) is one of the most common types of lung cancer and its poor prognosis largely depends on the tumor pathological stage. critical roles of microRNAs (miRNAs) have been reported in the tumorigenesis and progression of lung cancer. However, whether the differential expression pattern of miRNAs could be used to distinguish early-stage (stage I) from mid-late-stage (stages II-IV) LUAd tumors is still unclear. In this study, clinical information and miRNA expression profiles of patients with LUAd were downloaded from The cancer Genome Atlas (TcGA) and Gene Expression Omnibus databases. TcGA-LUAd (n=470) dataset was used for model training and validation, and the GSE62182 (n=94) and GSE83527 (n=36) datasets were used as external independent test datasets. The diagnostic model was created through miRNA feature selection followed by SVM classifier and was confirmed by 5-fold cross-validation. A receiver operating characteristic curve was calculated to evaluate the accuracy and robustness of the model. Using the dX score and LIBSVM tool, a 16-miRNA signature that could distinguish LUAd pathological stages was identified. The area under the curve rates were 0.62 [95% confidence interval (

show abstract

Section: Discussionmentioning

confidence: 99%

A novel microRNA signature for pathological grading in�lung adenocarcinoma based on TCGA and GEO data

Yang

Yin²,

Shi

et al. 2020

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…For example, a recent study showed that knockdown of DNMT3B altered the circular RNA expression, but was not related to changes in the linear host gene expression 20 . A recent study found that the transcription factor SOX9 can significantly upregulate the expression of hepatocellular carcinoma circFoxp1 21 . Therefore, the production of circFoxp1 is regulated by a variety of factors, which may be cell-specific.…”

Section: Discussionmentioning

confidence: 99%

A novel epigenetic regulation of circFoxp1 on Foxp1 in colon cancer cells

Luo

Liu

et al. 2020

Cell Death Dis

View full text Add to dashboard Cite

Foxp1 is a tumor suppressor in colon cancer. However, circFoxp1 derived from Foxp1 is an oncogene. In this study, we aim to investigate the role of circFoxp1 in colon cancer and the regulatory mechanism between circFoxp1 and Foxp1. 78 human colon tumor tissues and the matched paracancerous tissues were collected. Quantitative polymerase chain reaction, immunohistochemistry, quantitative methylation-specific PCR, chromatin immunoprecipitation assay, CCK-8 assay, and Tumor xenograft in nude mice were performed. The expression of circFoxp1 was increased and Foxp1 was reduced in colon cancer tissues, which were associated with a poor overall survival rate of the patients with colon cancer. CircFoxp1 recruited DNMT1 to the promoter of Foxp1, leading to promotor hypermethylation, thereby inhibiting Foxp1 transcription. Interfering circFoxp1 by siRNA in SW620 cells significantly inhibited cell viability, while knockdown Foxp1 expression partially restored SW620 cell viability. In addition, knockdown of circFoxp1 significantly sensitized colon cancer cells to Capecitabine in vitro and vivo through regulating Foxp1. We discovered a novel epigenetic pathway that circFoxp1 regulated Foxp1 in colon cancer cells. CircFoxp1 may regulate DNA methylation and demethylation to coordinate colon cancer cell proliferation and participate in chemotherapy drug responses. Therefore, circFoxp1 may be a potential therapeutic target for colon cancer.

show abstract

“…[5][6][7] Predecessors have confirmed that circRNAs are associated with the occurrence, development, and drug resistance of human diseases, such as Alzheimer's disease, hepatocellular carcinoma, lung cancer, breast cancer, and PC. [8][9][10][11][12] Previous studies have shown that circHIPK3 spongs miR-145-5p, miR-124, miR-558, miR-637, miR-193a, miR-338-3p, and miR-637 to regulate oxaliplatin-resistance, proliferation, tube formation, invasion, autophagy, migration, and apoptosis in lung cancer, preeclampsia, gastric cancer, colorectal cancer, chronic myeloid leukemia, bladder cancer, prostate cancer. [13][14][15][16][17][18][19][20] However, the role and function of circHIPK3 have not been revealed in PC.…”

Section: Introductionmentioning

confidence: 99%

<p>CircHIPK3 Promotes Gemcitabine (GEM) Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1</p>

Liu¹,

Li²,

Luo³

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Pancreatic cancer is one of the most common malignant diseases in the world. Gemcitabine chemotherapy remains the most important clinical treatment. However, research found that pancreatic cancer cells have chemoresistance to gemcitabine and the effect is not satisfactory. Therefore, it is urgent to find an effective early diagnosis and treatment strategy. Circular RNA is one of the most popular prognostic biomarkers in GEM-resistant PC. Materials and Methods: The present study was designed to evaluate the role of circHIPK3 in PC. The expression of circHIPK3 in PC tissues and cells and its effect on proliferation, migration, invasion, EMT, and apoptosis were investigated in vitro; its effect on tumor xenografts was assessed in vivo. Used bioinformation analysis to predict which miRNAs could potentially interact with circHIPK3, mRNA, and miR-330-5p. Results: RT-PCR showed that the level of circHIPK3 was increased in PC tumor tissues; moreover, circHIPK3 was also increased in GEM-resistant PC tumors tissues and GEMresistant PC cells. Sh-circHIPK3 could knockdown circHIPK3 in PANC-1-GEM and SW-1990-GEM and could significantly inhibit cell proliferation, invasion, migration, EMT and enhance cell apoptosis, compare with control group, the tumor xenografts of circHIPK3 knockdown group were significantly smaller. CircHIPK3 served as a sponge for miR-330-5p, and miR-330-5p directly bound to the 3′ UTR of RASSF1 were revealed by dual luciferase assay and RIP in PC cells. CircHIPK3 knockdown of RASSF1 expression could neutralize the cytological function of PC cells by miR-330-5p inhibitor mediated GEM-resistance. Conclusion: CircHIPK3 promotes gemcitabine (GEM) resistance in pancreatic cancer cells by targeting RASSF1 via miR-330-5p and regulates proliferation, invasive, migration, EMT, and apoptosis. Our research revealed that circHIPK3 may be a novel biomarker in GEMresistant PC and could be used as a prognostic target.

show abstract

Circular RNA circ-FOXP1 induced by SOX9 promotes hepatocellular carcinoma progression via sponging miR-875-3p and miR-421

Cited by 65 publications

References 26 publications

A novel microRNA signature for pathological grading in�lung adenocarcinoma based on TCGA and GEO data

A novel microRNA signature for pathological grading in�lung adenocarcinoma based on TCGA and GEO data

A novel epigenetic regulation of circFoxp1 on Foxp1 in colon cancer cells

<p>CircHIPK3 Promotes Gemcitabine (GEM) Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1</p>

Contact Info

Product

Resources

About